Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
The post PureTech Startup Gets $100M to Try For Success Where Sage & Others Fall Short in Depression appeared first on MedCity News.
Leave a comment